Introduction: The Red Maple Trials Naturalistic Exposure Chamber (NEC) is a fixed, live-cat exposure chamber, wherein allergen shed from two resident cats is aerosolized using a modified robot vacuum. The EnviroMini is a portable allergen exposure tent, in which allergen (Fel d 1, primarily) from milled cat hair is aerosolized in a similar manner. This is a single-center validation study designed to compare the allergic response to cat antigen provocation in the EnviroMini to the response in the previously validated NEC. Methods: Eight cat allergic subjects were randomized to undergo sequential 2-h allergen challenges in the EnviroMini and the NEC, 28 or more days apart. A modified robot vacuum aerosolized cat allergen in both chambers. Airborne Fel d 1 was measured using ELISA. Nasal, ocular, and chest symptoms were recorded every 10 min and spirometry every 20 min. Challenges were stopped and not repeated if FEV1 fell >20% of baseline during the exposure. Results: Fifteen subjects completed at least one challenge, and eight completed both (“per-protocol”). Mean total nasal symptom score (TNSS) averaged over the last 30 min (“plateau”) was not significantly different between the EnviroMini and NEC (paired t test, p = 0.16; mean [SE] 6.1 [1.2] and 4.5 [0.6], EnviroMini and NEC, respectively). There was no difference in FEV1 change between the two challenges (p = 0.90). The same results were found for all subjects as for the per-protocol group. TNSS plateau was not correlated with Fel d 1 exposure, and there was no difference in average Fel d 1 concentrations between the chambers (EnviroMini: 55; NEC: 54 ng/m3). Conclusion: The EnviroMini offers comparable cat allergen exposure and nasal and respiratory responses to the NEC. Its portability facilitates expansion to multisite chamber studies for clinical validation of allergy therapies. Future work could expand its capabilities to other aeroallergens.

1.
Grönlund
H
,
Saarne
T
,
Gafvelin
G
,
van Hage
M
.
The major cat allergen, Fel d 1, in diagnosis and therapy
.
Int Arch Allergy Immunol
.
2010
;
151
(
4
):
265
74
.
2.
Satyaraj
E
,
Wedner
HJ
,
Bousquet
J
.
Keep the cat, change the care pathway: a transformational approach to managing Fel d 1, the major cat allergen
.
Allergy
.
2019
;
74
(
Suppl 107
):
5
17
.
3.
Zahradnik
E
,
Raulf
M
.
Animal allergens and their presence in the environment
.
Front Immunol
.
2014
;
5
(
MAR
):
76
21
.
4.
Rösner-Friese
K
,
Kaul
S
,
Vieths
S
,
Pfaar
O
.
Environmental exposure chambers in allergen immunotherapy trials: current status and clinical validation needs
.
J Allergy Clin Immunol
.
2015
;
135
(
3
):
636
43
.
5.
Custovic
A
,
Simpson
A
,
Pahdi
H
,
Green
RM
,
Chapman
MD
,
Woodcock
A
.
Distribution, aerodynamic characteristics, and removal of the major cat allergen Fel d 1 in British homes
.
Thorax
.
1998
;
53
(
1
):
33 LP
38
.
6.
Pfaar
O
,
Calderon
MA
,
Andrews
CP
,
Angjeli
E
,
Bergmann
KC
,
Bønløkke
JH
, et al
.
Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper
.
Allergy
.
2017
;
72
(
7
):
1035
42
.
7.
Patel
D
,
Couroux
P
,
Hickey
P
,
Salapatek
AM
,
Laidler
P
,
Larché
M
, et al
.
Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study
.
J Allergy Clin Immunol
.
2013
;
131
(
1
):
103
9.e97
.
8.
de Blay
FJ
,
Gherasim
A
,
Domis
N
,
Meier
P
,
Shawki
F
,
Wang
CQ
, et al
.
REGN1908/1909 prevented cat allergen–induced early asthmatic responses in an environmental exposure unit
.
J Allergy Clin Immunol
.
2022
;
150
(
6
):
1437
46
.
9.
Corren
J
,
Wood
RA
,
Patel
D
,
Zhu
J
,
Yegin
A
,
Dhillon
G
, et al
.
Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge
.
J Allergy Clin Immunol
.
2011
;
127
(
2
):
398
405
.
10.
Corren
J
,
Spector
S
,
Fuller
L
,
Minkwitz
M
,
Mezzanotte
W
.
Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure
.
Ann Allergy Asthma Immunol
.
2001
;
87
(
3
):
211
7
.
11.
Perry
TT
,
Corren
J
,
Philip
G
,
Kim
EH
,
Conover-Walker
MK
,
Malice
MP
, et al
.
Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure
.
Ann Allergy Asthma Immunol
.
2004
;
93
(
5
):
431
8
.
12.
Yang
WH
,
Kelly
S
,
Haya
L
,
Mehri
R
,
Ramesh
D
,
DeVeaux
M
, et al
.
Cat allergen exposure in a naturalistic exposure chamber: a prospective observational study in cat-allergic subjects
.
Clin Exp Allergy
.
2022
;
52
(
2
):
265
75
.
13.
Haya
LK
,
Mehri
R
,
Somers-Neal
S
,
Van de Mosselaer
S
,
Spence
A
,
Kelly
SM
, et al
.
Automated dander dispersal in a cat naturalistic exposure chamber (NEC)
.
Allergy
.
2022
;
77
(
2
):
685
7
.
14.
Haya
L
,
Kelly
S
,
Matida
E
,
Mehri
R
,
Yang
W
,
Van de Mosselaer
S
.
Systems et Methods de Chambre de Dispersion et d’Exposition, dispersal and exposure chamber systems and methods
.
2023
.
15.
Zubair
A
,
Kelly
S
,
Siddiqui
K
,
Albasser
M
,
Maybaum
N
,
McCloskey
N
, et al
.
Visualizing fluticasone propionate’s impact on allergic rhinitis facial symptoms: photographic and thermographic imaging pilot study
.
Ann Allergy Asthma Immunol
.
2024
;
133
(
6
):
S95
.
16.
Zielen
S
,
Trischler
J
,
Schubert
R
.
Lipopolysaccharide challenge: immunological effects and safety in humans
.
Expert Rev Clin Immunol
.
2015
;
11
(
3
):
409
18
.
17.
Pfaar
O
,
Bergmann
K
,
Bonini
S
,
Compalati
E
,
Domis
N
,
de Blay
F
, et al
.
Technical standards in allergen exposure chambers worldwide: an EAACI Task Force Report
.
Allergy
.
2021
;
76
(
12
):
3589
612
.
18.
Larson
D
,
Patel
P
,
Salapatek
AM
,
Couroux
P
,
Whitehouse
D
,
Pina
A
, et al
.
Nasal allergen challenge and environmental exposure chamber challenge: a randomized trial comparing clinical and biological responses to cat allergen
.
J Allergy Clin Immunol
.
2020
;
145
(
6
):
1585
97
.
19.
Jabbal
S
,
Poli
G
,
Lipworth
B
.
Does size really matter? relationship of particle size to lung deposition and exhaled fraction
.
J Allergy Clin Immunol
.
2017
;
139
(
6
):
2013
4.e1
.
20.
Olivieri
M
,
Heinrich
J
,
Schlünssen
V
,
Antó
JM
,
Forsberg
B
,
Janson
C
, et al
.
The risk of respiratory symptoms on allergen exposure increases with increasing specific IgE levels
.
Allergy
.
2016
;
71
(
6
):
859
68
.
21.
Bollinger
ME
,
Eggleston
PA
,
Flanagan
E
,
Wood
RA
.
Cat antigen in homes with and without cats may induce allergic symptoms
.
Am J Rhinol
.
1996
;
10
(
4
):
264
5
.
22.
Luczynska
CM
,
Li
Y
,
Chapman
MD
,
Platts-Mills
TA
.
Airborne concentrations and particle size distribution of allergen derived from domestic cats (Felis domesticus). Measurements using cascade impactor, liquid impinger, and a two-site monoclonal antibody assay for Fel d I
.
Am Rev Respir Dis
.
1990
;
141
(
2
):
361
7
.
23.
Krug
N
,
Hohlfeld
JM
,
Larbig
M
,
Buckendahl
A
,
Badorrek
P
,
Geldmacher
H
, et al
.
Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis
.
Clin Exp Allergy
.
2003
;
33
(
12
):
1667
74
.
24.
Zuberbier
T
,
Abelson
MB
,
Akdis
CA
,
Bachert
C
,
Berger
U
,
Bindslev-Jensen
C
, et al
.
Validation of the Global Allergy and Asthma European Network (GA2LEN) chamber for trials in allergy: innovation of a mobile allergen exposure chamber
.
J Allergy Clin Immunol
.
2017
;
139
(
4
):
1158
66
.
25.
Zieglmayer
PU
.
Are results of environmental exposure units transferable to real-life exposure
.
Curr Opin Allergy Clin Immunol
.
2013
;
13
(
3
):
244
8
.
26.
Couroux
P
,
Patel
D
,
Armstrong
K
,
Larché
M
,
Hafner
RP
.
Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects
.
Clin Exp Allergy
.
2015
;
45
(
5
):
974
81
.
27.
Voegler
T
,
Goergen
F
,
Bergmann
KC
,
Boelke
G
,
Salame
J
,
Gildemeister
J
, et al
.
Technical specifications of the global allergy and asthma european network (GA2LEN) chamber: a novel mobile allergen exposure chamber
.
Allergo J
.
2017
;
26
(
8
):
20
7
.
You do not currently have access to this content.